Tenax Therapeutics Inc Cash Flow Conversion Efficiency
Tenax Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Tenax Therapeutics Inc (TENX) has a cash flow conversion efficiency ratio of -0.125x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.15 Million) by net assets ($113.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Tenax Therapeutics Inc (1995–2025)
Cash flow conversion efficiency of Tenax Therapeutics Inc from 1995 to 2025. This chart illustrates how Tenax Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Tenax Therapeutics Inc stock price for real-time trading data and today's change.
Tenax Therapeutics Inc Cash Flow Conversion Ratio Explained
Tenax Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Tenax Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tenax Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Tenax Therapeutics Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GIIB Holdings Bhd
KLSE:7192
|
-0.621x |
|
Alkim Alkali Kimya AS
IS:ALKIM
|
0.070x |
|
Wentel Engineering Holdings Berhad
KLSE:0298
|
0.039x |
|
Feelux Co. Ltd.
KO:033180
|
-0.009x |
|
Mawana Sugars Limited
NSE:MAWANASUG
|
0.839x |
|
Korea Computer & Systems Inc
KQ:115500
|
0.039x |
|
Enzymatica publ AB
ST:ENZY
|
-0.085x |
|
L.P.N. Development Public Company Limited
BK:LPN
|
0.018x |
Annual Cash Flow Conversion Efficiency for Tenax Therapeutics Inc (1995–2025)
The table below shows the annual cash flow conversion efficiency of Tenax Therapeutics Inc from 1995 to 2025. Review Tenax Therapeutics Inc free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $97.07 Million | $-35.80 Million | -0.369x | -129.07% |
| 2024-12-31 | $91.99 Million | $-14.81 Million | -0.161x | +77.92% |
| 2023-12-31 | $8.10 Million | $-5.90 Million | -0.729x | +90.94% |
| 2022-12-31 | $1.49 Million | $-12.01 Million | -8.048x | -214.65% |
| 2021-12-31 | $4.24 Million | $-10.86 Million | -2.558x | -27.58% |
| 2020-12-31 | $4.63 Million | $-9.27 Million | -2.005x | -0.09% |
| 2019-12-31 | $3.77 Million | $-7.56 Million | -2.003x | -328.73% |
| 2018-12-31 | $11.77 Million | $-5.50 Million | -0.467x | +65.82% |
| 2017-12-31 | $8.88 Million | $-12.14 Million | -1.367x | -47.62% |
| 2016-12-31 | $17.14 Million | $-15.87 Million | -0.926x | -473.89% |
| 2015-12-31 | $60.42 Million | $-9.75 Million | -0.161x | -44.39% |
| 2014-12-31 | $82.89 Million | $-9.26 Million | -0.112x | 0.00% |
| 2013-12-31 | $82.89 Million | $-9.26 Million | -0.112x | +31.20% |
| 2012-12-31 | $30.30 Million | $-4.92 Million | -0.162x | -101.68% |
| 2011-12-31 | $-871.46K | $-8.40 Million | 9.643x | +338.84% |
| 2010-12-31 | $2.13 Million | $-8.59 Million | -4.037x | -281.02% |
| 2009-12-31 | $3.83 Million | $-4.06 Million | -1.060x | -207.36% |
| 2008-12-31 | $6.60 Million | $-2.28 Million | -0.345x | -113.89% |
| 2007-12-31 | $-458.25K | $-1.14 Million | 2.483x | +121.52% |
| 2006-12-31 | $186.22K | $-2.15 Million | -11.537x | -449.29% |
| 2005-12-31 | $948.40K | $-1.99 Million | -2.100x | -71.48% |
| 2004-12-31 | $1.45 Million | $-1.77 Million | -1.225x | +32.60% |
| 2003-12-31 | $1.15 Million | $-2.09 Million | -1.817x | -18.33% |
| 2002-12-31 | $1.24 Million | $-1.90 Million | -1.536x | -239.02% |
| 2001-12-31 | $3.39 Million | $-1.54 Million | -0.453x | -190.35% |
| 2000-12-31 | $5.85 Million | $-913.30K | -0.156x | -101.95% |
| 1999-12-31 | $-100.00K | $-800.00K | 8.000x | +588.53% |
| 1998-12-31 | $351.55K | $-575.69K | -1.638x | -153.05% |
| 1997-12-31 | $-282.51K | $-872.15K | 3.087x | +20.56% |
| 1996-12-31 | $-597.60K | $-1.53 Million | 2.561x | 0.00% |
| 1995-12-31 | $-597.60K | $-1.53 Million | 2.561x | -- |
About Tenax Therapeutics Inc
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imat… Read more